Zacks: Evotec AG (NASDAQ:EVTCY) Given Consensus Rating of “Strong Buy” by Analysts
Evotec AG (NASDAQ:EVTCY) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Zacks has also assigned Evotec AG an industry rank of 80 out of 265 based on the ratings given to related companies.
Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of Evotec AG from a “hold” rating to a “strong-buy” rating and set a $11.00 price objective on the stock in a research report on Friday, August 12th. DZ Bank AG reiterated a “buy” rating on shares of Evotec AG in a research report on Monday, July 11th.
Shares of Evotec AG (NASDAQ:EVTCY) remained flat at $10.18 during trading on Monday. The stock’s 50 day moving average is $9.75 and its 200 day moving average is $8.48. The company has a market capitalization of $674.67 million and a price-to-earnings ratio of 115.68. Evotec AG has a 12 month low of $6.56 and a 12 month high of $10.22.
Evotec AG Company Profile
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator’s targets and programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.